Atlas Trials

Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy

Clinical trial NCT03205033 · COMPLETED

Trial details

NCT number
NCT03205033
Sponsor
Hospital de Clinicas de Porto Alegre
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Sleep Disorders, Circadian RhythmDepressionGenotoxicityPain
Start date
2016-01-01
Primary completion
2017-01-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.